ClinicalTrials.gg
RecruitingNCT07049926Updated Oct 27, 2026

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

A Phase 1/2 interventional study of Belzutifan and Zanzalintinib in Renal Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Recruiting at 33 sites in 8 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 27, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing zanzalintinib in Carcinoma, Renal Cell — 10 open to participants now, 12 under way, 4 of them phase 3. zanzalintinib · Carcinoma, Renal Cell.

Planned enrollment
7th of 13
140 · median 140
Started
2025
with 2 others
Phase 1/2
Only one
of the 13
Primary completion
2031-10
later than 10 of 11 live
Registered
8th of 13
by date
Lead sponsor
3 of 13
Merck Sharp & Dohme LLC

Among the 13 studies testing zanzalintinib in Carcinoma, Renal Cell, this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 1/2, reaches primary completion later than 10 of the 11 other live ones, and was the 8th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 13 studies testing zanzalintinib in Carcinoma, Renal Cell are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About zanzalintinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing zanzalintinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).

The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-[L]1) adjuvant therapy.

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study

03

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI)
  • Hypoxia-Inducible Factor-2α (HIF-2α)
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Has a confirmed diagnosis of unresectable locally advanced/ renal cell carcinoma (RCC) with clear cell component
  • Has received no other prior systemic therapy for treatment of advanced/metastatic clear cell renal cell carcinoma (ccRCC) except for adjuvant programmed cell death ligand 1 (PD-(L)1) therapy
  • Has disease recurrence during anti- PD-(L)1 therapy or ≤24 months following the last dose of adjuvant anti-PD-(L)1 therapy
  • Is able to swallow oral medication
  • Submits an sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
  • Participants receiving bone resorptive therapy (must have therapy initiated at least 2 weeks before allocation/randomization)
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤140/90 mm Hg with no change in antihypertensive medications within 1 week before allocation/randomization
  • Has adequate organ function

The main exclusion criteria include but are not limited to the following:

  • Has hematuria, hematemesis, or hemoptysis of (>2.5 mL) of red blood, or other history of significant bleeding
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
  • Has deep vein thrombosis within 3 months before allocation/randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before allocation/randomization
  • Has history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis
  • Has serious wound, ulcer or bone fracture or has had major surgery within 8 weeks before first dose of study intervention
  • Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage in the last 4 weeks before allocation/randomization
  • Has gastrointestinal (GI) disorders, including those associated with a high risk of perforation or fistula formation
  • Has malabsorption due to prior GI surgery or GI disease
  • Has moderate to severe hepatic impairment
  • Has received colony-stimulating factors within 28 days prior to intervention allocation/randomization
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Is currently receiving strong inhibitors of cytochrome P450 3A4 () that cannot be discontinued for the duration of the study
  • Has received a live or within 30 days before the first dose of study intervention
  • Is currently receiving anticoagulants or inhibitors that cannot be discontinued for the duration of the study
  • Have been previously allocated/randomized to study intervention in any sub study of protocol MK-3475-U03
  • Has a known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation
  • Has active disease that has required systemic treatment in the past 2 years
  • Has an active infection requiring systemic therapy
  • Has history of (HIV) infection
  • Has or virus infection
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Zanzalintinib at Dose Level 1 or 2 + Belzutifan

    Participants will be allocated to receive zanzalintinib at dose level 1 or 2 + belzutifan daily until progressive disease or discontinuation

    Drug: Belzutifan · Drug: Zanzalintinib

  • Experimental
    Belzutifan

    Participants will receive belzutifan daily until progressive disease or discontinuation

    Drug: Belzutifan

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)

    DLTs are defined as any of a pre-specified list of toxicities if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration, excluding toxicities clearly not related to the drug, such as disease progression, environmental factors, unrelated trauma, etc.

    Time frame: Up to approximately 21 days

  2. Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 74 months

  3. Safety Lead In Phase: Number of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 74 months

  4. Efficacy Phase: Number of participants who experience one or more DLTs

    DLTs are defined as any of a pre-specified list of toxicities if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration, excluding toxicities clearly not related to the drug, such as disease progression, environmental factors, unrelated trauma, etc.

    Time frame: Up to approximately 21 days

  5. Efficacy Phase: Number of participants who experience one or more AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 74 months

  6. Efficacy Phase: Number of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 74 months

  7. Efficacy Phase: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 74 months

Secondary outcomes

  1. Efficacy Phase: Duration of response (DOR)

    For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 74 months

  2. Efficacy Phase: Progression-free survival (PFS)

    PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 74 months

  3. Efficacy Phase: Overall survival (OS)

    OS is defined as time from first dose of study treatment to death due to any cause.

    Time frame: Up to approximately 74 months

  4. Efficacy Phase: Clinical benefit rate (CBR)

    CBR is defined as the percentage of participants who have achieved stable disease (SD: Neither sufficient shrinkage to qualify for PR \[at least a 30% decrease in the sum of diameters of target lesions\] nor sufficient increase to qualify for PD) of ≥6 months or confirmed CR (disappearance of all target lesions) or PR per RECIST 1.1. PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The CBR as assessed by BICR will be presented.

    Time frame: Up to approximately 74 months

07

Study locations

33 of 33 sites recruiting
  • UCSF Medical Center at Mission Bay ( Site 5008)
    San Francisco, California 94158, United States
    Recruiting
    • Study Coordinator · Contact415-694-3896
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026)
    Mineola, New York 11501, United States
    Recruiting
    • Study Coordinator · Contact516-663-3696
  • Laura and Isaac Perlmutter Cancer Center ( Site 5016)
    New York, New York 10016, United States
    Recruiting
    • Study Coordinator · Contact212-731-6000
  • Memorial Sloan Kettering Cancer Center ( Site 5002)
    New York, New York 10065, United States
    Recruiting
    • Study Coordinator · Contact212-639-2000
  • Duke Cancer Institute ( Site 5015)
    Durham, North Carolina 27710, United States
    Recruiting
    • Study Coordinator · Contact919-681-1030
  • UPMC Cancer Center/Hillman Cancer Center ( Site 5017)
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Study Coordinator · Contact412-864-6600
  • Vanderbilt University Medical Center ( Site 5004)
    Nashville, Tennessee 37232, United States
    Recruiting
    • Study Coordinator · Contact615-343-2882
  • Centro de Estudios Clínicos SAGA ( Site 6110)
    Santiago, Region M. de Santiago 7500653, Chile
    Recruiting
    • Study Coordinator · Contact+56223592703
  • CDIEM ( Site 6114)
    Santiago, Region M. de Santiago 7500859, Chile
    Recruiting
    • Study Coordinator · Contact+56227435608
  • Bradfordhill ( Site 6101)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203)
    Strasbourg, Bas-Rhin 67098, France
    Recruiting
    • Study Coordinator · Contact+330368767150
  • Institut Claudius Regaud ( Site 5200)
    Toulouse, Haute-Garonne 31059, France
    Recruiting
    • Study Coordinator · Contact+33531155050
  • Centre Eugene Marquis ( Site 5205)
    Rennes, Ille-et-Vilaine 35042, France
    Recruiting
    • Study Coordinator · Contact+33299253182
  • Institut De Cancerologie De Lorraine ( Site 5204)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54513, France
    Recruiting
    • Study Coordinator · Contact+33383598574
  • Gustave Roussy ( Site 5202)
    Villejuif, Île-de-France Region 94805, France
    Recruiting
    • Study Coordinator · Contact0033142116690
  • Rambam Health Care Campus ( Site 5500)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact972-4-7776234
  • Rabin Medical Center ( Site 5502)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239378110
  • Sheba Medical Center ( Site 5501)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+972-35304498
  • Sourasky Medical Center ( Site 5503)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact97236947284
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 6201)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
    Recruiting
    • Study Coordinator · Contact52 374 38 62
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie ( Site 6203)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48 22 546 23 31
  • Uniwersyteckie Centrum Kliniczne ( Site 6202)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
    • Study Coordinator · Contact+48585844466
  • Severance Hospital ( Site 5802)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact82-2-2228-8138
  • Asan Medical Center ( Site 5800)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230106981
  • Samsung Medical Center ( Site 5801)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82-2-3410-3459
  • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 5302)
    Madrid, Madrid, Comunidad de 28007, Spain
    Recruiting
    • Study Coordinator · Contact+34915868000
  • Hospital Universitario Ramon y Cajal ( Site 5301)
    Madrid, Madrid, Comunidad de 28034, Spain
    Recruiting
    • Study Coordinator · Contact+34913368263
  • Hospital Universitari Vall d'Hebron ( Site 5300)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34934894350
  • Western General Hospital ( Site 5402)
    Edinburgh, Edinburgh, City of EH42XU, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441315371000
  • The Beatson West of Scotland Cancer Centre ( Site 5405)
    Glasgow, Glasgow City G12 0YN, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441413017064
  • St Bartholomew's Hospital ( Site 5401)
    London, London, City of EC1A7BE, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442072533411
  • Velindre Cancer Centre ( Site 5407)
    Cardiff, CF14 2TL, United Kingdom
    Recruiting
    • Study Coordinator · Contact+442920615888
  • The Christie NHS Foundation Trust ( Site 5400)
    Manchester, M20 4BX, United Kingdom
    Recruiting
    • Study Coordinator · Contact+441614463988
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Oct 2031, 75 months after the start.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 75 months is above that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 3, 2025
StartActual
Jul 20, 2025
Primary completionEst.
Oct 26, 2031
CompletionEst.
Oct 26, 2031
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Rambam Health Care Campus ( Site 5500) · Haifa, IsraelActive, not recruiting→Recruiting
  • Rabin Medical Center ( Site 5502) · Petah Tikva, IsraelActive, not recruiting→Recruiting
  • Sheba Medical Center ( Site 5501) · Ramat Gan, IsraelActive, not recruiting→Recruiting
  • Sourasky Medical Center ( Site 5503) · Tel Aviv, IsraelActive, not recruiting→Recruiting
Show site
  • CDIEM ( Site 6114) · Santiago, Chile
across 2 updates, Oct 2, 2026 – Oct 27, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Rambam Health Care Campus ( Site 5500) · Haifa, IsraelContact added •••6234
  • Rabin Medical Center ( Site 5502) · Petah Tikva, IsraelContact added •••8110
  • Sheba Medical Center ( Site 5501) · Ramat Gan, IsraelContact added •••4498
  • Sourasky Medical Center ( Site 5503) · Tel Aviv, IsraelContact added •••7284
Oct 2, 2026
Show all 2 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • CDIEM ( Site 6114) · Santiago, Chile
    + 2 other changes: verification date and references
  2. Oct 2, 2026
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Rambam Health Care Campus ( Site 5500) · Haifa, IsraelActive, not recruiting→Recruiting
    • Rabin Medical Center ( Site 5502) · Petah Tikva, IsraelActive, not recruiting→Recruiting
    • Sheba Medical Center ( Site 5501) · Ramat Gan, IsraelActive, not recruiting→Recruiting
    • Sourasky Medical Center ( Site 5503) · Tel Aviv, IsraelActive, not recruiting→Recruiting
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Rambam Health Care Campus ( Site 5500) · Haifa, IsraelContact added •••6234
    • Rabin Medical Center ( Site 5502) · Petah Tikva, IsraelContact added •••8110
    • Sheba Medical Center ( Site 5501) · Ramat Gan, IsraelContact added •••4498
    • Sourasky Medical Center ( Site 5503) · Tel Aviv, IsraelContact added •••7284

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07049926
Collaborators
Exelixis
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Jul 20, 2025
Primary completion
Oct 26, 2031 (estimated)
Completion
Oct 26, 2031 (estimated)
Last update
Oct 27, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion